Search

Nebulized gamma interferon (IFN-γ) protein has been studied for clinical safety and efficacy against pulmonary tuberculosis (TB). The protein is expensive, requires a cold chain, and is difficult to deploy in limited-resource, high-incidence settings. We generated preclinical proof of concept (PoC) for a dry powder inhalation (DPI) containing DNA constructs to transiently transfect the lung and airway epithelium of mice with murine IFN-γ. Bacterial colony forming units (CFU) in the lungs of mice infected with Mycobacterium tuberculosis (Mtb) reduced from about 106/g of tissue to ∼104 after four doses given once a week. Nodular inflammatory lesions in the lungs reduced significantly in number. Immunohistochemistry of infected lung sections for LC3-1 and LAMP-1 indicated autophagy induction between 18-48h after inhalation. ELISA on bronchioalveolar lavage (BAL) fluid showed differences in kinetics of IFN-γ concentrations in the epithelial lining fluid of healthy versus infected mice. Uninfected mice receiving DNA constructs expressing a fluorescent protein were live-imaged. The fluorescence signals from the intracellular protein peaked at about 36h after inhalation and declined by 48h. These results establish preclinical PoC of the efficacy of a DPI and dosing regimen as host-directed and transient gene therapy of experimental pulmonary TB in mice, justifying preclinical development., Graphical Abstract, Misra and colleagues present preclinical proof-of-concept that transiently transfecting the lung epithelium by means of inhaled DNA encoding gamma interferon is efficacious in treating mice infected with Mycobacterium tuberculosis. They argue that their non-sterile, non-invasive and potentially storage-stable dry powder inhalation formulation of plasmid DNA has advantages over nebulized protein.

Amphotericin B (AmB) exhibits potential antileishmanial activity, with only a little rate of recurrence. However, low bioavailability and severe nephrotoxicity are among the major shortcomings of AmB-based therapy. Various AmB nanoformulations have been developed, which to an extent, have reduced its toxicity and increased the drug efficacy. To further reduce the nonspecific tissue distribution and the cost of the treatment, the current AmB-based formulations require additional improvements. Combination of natural bioenhancers with AmB is expected to further increase its bioavailability. Therefore, we developed a nanoformulation of AmB and piperine (Pip), a plant alkaloid, known to enhance the bioavailability of various drugs, by entrapping them in guar gum, a macrophage targeting polymer. Owing to the ease of oral delivery, these nanoparticles (NPs) were coated with eudragit to make them suitable for oral administration. The formulated eudragit-coated AmB and Pip-loaded NPs (Eu-HDGG-AmB-Pip-NPs) exhibited controlled release of the loaded therapeutic agents and protected the drug from acidic pH. These NPs exhibited effective suppression of growth of both promastigotes and amastigotes of Leishmania donovani parasite under in vitro. In vivo evaluation of these NPs for therapeutic efficacy in golden hamster-L. donovani model demonstrated enhanced drug bioavailability, non-nephrotoxic nature, and potential antileishmanial activity with up to 96% inhibition of the parasite. Graphical abstract.

It is unclear whether Vitamin D is efficacious as a host-directed therapy (HDT) for patients of tuberculosis (TB). We investigated pulmonary delivery of the active metabolite of Vitamin DWe optimized a spray drying process to prepare a dry powder inhalation (DPI) of calcitriol using a Quality by Design (QbD) approach. We then compared outcomes when Mtb-infected mice were treated with inhaled calcitriol at 5 ng/kg as a stand-alone intervention versus DPI as adjunct to standard oral anti-tuberculosis therapy (ATT).The DPI with or without concomitant ATT markedly improved the morphology of the lungs and mitigated histopathology in both the lungs and the spleens. The number of nodular lesions on the lung surface decreased from 43.7 ± 3.1 to 22.5 ± 3.9 with the DPI alone and to 9.8 ± 2.5 with DPI + ATT. However, no statistically significant induction of host antimicrobial peptide cathelicidin or reduction in bacterial burden was seen with the DPI alone. DPI + ATT did not significantly reduce the bacterial burden in the lungs compared to ATT alone.We concluded that HDT using the low dose calcitriol DPI contributed markedly to mitigation of pathology, but higher dose may be required to evoke significant induction of bactericidal host response and bactericidal activity in the lung.

Transient transfection of the respiratory mucosa of mice infected with Mycobacterium tuberculosis (Mtb) with gamma interferon (IFN-γ) promises benefits in disease therapy. We investigated preclinical efficacy of a dry powder inhalation (DPI) as a stand-alone versus adjunct to oral anti-tuberculosis (TB) chemotherapy in mice. We observed that this host-directed therapy mitigates the gross organ pathology and histopathology of lung and spleen tissue of infected mice receiving the DPI, either alone or as adjunct therapy. However, no statistically significant reduction in Mtb colony forming units (CFU) occurred if mice were given only DPI; but not drugs. We compared one and three doses a week of the DPI over four weeks; with or without concomitant oral drugs. There was no significant difference in lung CFU after four or 12 doses of the DPI alone, but, surprisingly, four doses were qualitatively better than 12 doses in mitigating lung pathology. Nodular lesions on the lung surface and the area occupied by these was significantly reduced after four doses of the DPI, even without oral drugs. Transient transfection with IFN-γ did not induce pathological inflammation of the lungs and airways. We conclude that IFN-γ, as expected of host-directed therapy, 'heals the host; ' but does not 'kill the bug.'

Amphotericin B (AmB) exhibits potential antileishmanial activity, with only a little rate of recurrence. However, low bioavailability and severe nephrotoxicity are among the major shortcomings of AmB-based therapy. Various AmB nanoformulations have been developed, which to an extent, have reduced its toxicity and increased the drug efficacy. To further reduce the nonspecific tissue distribution and the cost of the treatment, the current AmB-based formulations require additional improvements. Combination of natural bioenhancers with AmB is expected to further increase its bioavailability. Therefore, we developed a nanoformulation of AmB and piperine (Pip), a plant alkaloid, known to enhance the bioavailability of various drugs, by entrapping them in guar gum, a macrophage targeting polymer. Owing to the ease of oral delivery, these nanoparticles (NPs) were coated with eudragit to make them suitable for oral administration. The formulated eudragit-coated AmB and Pip-loaded NPs (Eu-HDGG-AmB-Pip-NPs) exhibited controlled release of the loaded therapeutic agents and protected the drug from acidic pH. These NPs exhibited effective suppression of growth of both promastigotes and amastigotes of Leishmania donovani parasite under in vitro. In vivo evaluation of these NPs for therapeutic efficacy in golden hamster-L. donovani model demonstrated enhanced drug bioavailability, non-nephrotoxic nature, and potential antileishmanial activity with up to 96% inhibition of the parasite. Graphical abstract.

A spray drying process was standardized to prepare an inhalable powder comprising d -cycloserine and ethionamide, two “second line” drugs employed for treating multi-drug resistant (MDR) tuberculosis (TB). The aim of the process development effort was to maximize product yield. Contour plots were generated using a small central composite design (CCD) with face centered (α = 1) to maximize the process yield as the response criterion. The design space was experimentally validated. Powder was prepared and characterized for drug content (HPLC), geometric size (laser scattering), surface morphology (scanning electron microscopy) aerosol behaviour (cascade impaction) and powder flow properties. The optimized process yielded a powder with a median mass aerodynamic diameter (MMAD) of 1.76 µ ± 3.1 geometric standard deviation (GSD). Mass balance indicated that the major proportion of the particles produced by spray drying are lost to the outlet filter. The process represents a best-case compromise of spray-drying conditions to minimize loss during droplet drying, collection and process air discharge.

The anticancer properties of selenium (Se) and curcumin nanoparticles in solo formulations as well as in combination with other therapeutic agents have been proved time and again. Exploiting this facet of the two, we clubbed their tumoricidal characteristics and designed curcumin loaded Se nanoparticles (Se-CurNPs) to achieve an enhanced therapeutic effect. We evaluated their therapeutic effects on different cancer cell lines and Ehrlich's ascites carcinoma mouse model. In vitro results showed that Se-CurNPs were most effective on colorectal carcinoma cells (HCT116) compared to the other cancer cell lines used and possessed pleiotropic anticancer effects. The therapeutic effect on HCT116 was primarily attributed to an elevated level of autophagy and apoptosis as evident from significant up-regulation of autophagy associated (LC3B-II) and pro-apoptotic (Bax) proteins, down-regulation of anti-apoptotic (Bcl-2) protein and Cytochrome c (cyt c) release from mitochondria along with reduced NFκB signaling and EMT based machineries marked by downregulation of inflammation (NFκB, phospho-NFκB) and epithelial-mesenchymal transition (CD44, N-cadherin) associated proteins. In vivo studies on Ehrlich's ascites carcinoma (EAC) mice model indicated that Se-CurNPs significantly reduced the tumor load and enhanced the mean survival time (days) of tumor-bearing EAC mice.

We compared the pharmacokinetics and efficacy of a combination of d-cycloserine (DCS) and ethionamide (ETO) via oral and inhalation routes in mice. The plasma half-life (t 1/2) of oral ETO at a human-equivalent dose decreased from 4.63 ± 0.61 h to 1.64 ± 0.40 h when DCS was coadministered. The area under the concentration-time curve from 0 h to time t (AUC0- t ) was reduced to one-third. Inhalation overcame the interaction. Inhalation, but not oral doses, reduced the lung CFU/g of Mycobacterium tuberculosis H37Rv from 6 to 3 log10 in 4 weeks, indicating bactericidal activity.

We compared the pharmacokinetics and efficacy of a combination of d-cycloserine (DCS) and ethionamide (ETO) via oral and inhalation routes in mice. The plasma half-life (t(1/2)) of oral ETO at a human-equivalent dose decreased from 4.63 ± 0.61 h to 1.64 ± 0.40 h when DCS was coadministered. The area under the concentration-time curve from 0 h to time t (AUC(0–)(t)) was reduced to one-third. Inhalation overcame the interaction. Inhalation, but not oral doses, reduced the lung CFU/g of Mycobacterium tuberculosis H37Rv from 6 to 3 log(10) in 4 weeks, indicating bactericidal activity.

Stroke is one of the major causes of death worldwide, and the thrombolytic drug alteplase (tissue plasminogen activator or tPA) is the only treatment available for acute ischemic stroke; however, its use is limited by its short therapeutic window. Many potential therapeutic and diagnostic neuroprotectants to the brain are available, but, unfortunately, most of them are limited by the blood-brain barrier (BBB). Conversely, nanoparticles (NPs) easily cross the BBB with no undesired side effect and alteration of the integrity of BBB. Thus, NPs have created new facet in stroke therapy. The nanocarriers-based preclinical and clinical research in thrombolytic drug delivery is mentioned. Preclinical research carried out on different thrombolytic drug-loaded polymer, lipid, and magnetic nanoparticles showed an enhanced thrombolytic effect with least adverse effects. Targeted nanocarriers displayed an enhanced accumulation into thrombolytic area. NP-based drug delivery opens up new route for the management of thrombotic diseases.

Nanotechnology has transformed cancer diagnosis and therapeutics enormously over the past decade and is the origin of the field of cancer nanomedicine. Nanotechnology has gained huge popularity, especially in the case of cancer therapeutics, due to its potential to deliver hydrophobic drugs effectively with enhanced therapeutic effect whilst also targeting the specific disease area. At present, numerous nanoparticle formulations are used in cancer therapeutics, including polymeric, lipid-based, metal-based, mesoporous silica, and magnetic. In this chapter we only focus on the polymeric nanocarriers and their therapeutic efficacies in lung cancer. Innovative engineering on polymeric nanocarriers allows multiple anticancer drugs and gene delivery to site-specific targets. Nanoparticle-based therapeutics in lung cancer is an emerging area and covers the diagnosis, screening, imaging, and treatment of primary and metastatic lung tumors. However, promising results in the laboratory are often hampered severely due to the challenges regarding nanoparticles in the areas of large-scale manufacturing, toxicology, pharmacology, immunology, and regulatory issues.

Melanoma is notorious and very aggressive skin cancer which is well known for its multidrug resistance. Thus, patients having melanoma have a low survival rate. Traditional anticancer treatment for melanoma with dacarbazine, interleukin-2 and interferon-alpha-2b, etc., showed low response and survival rates. However, recently targeted nanoparticle-based therapy displayed good response with better survival rates in melanoma-bearing patients. Better survival rate with very low adverse effects has been observed with targeted nanomedicines in animal models. Thus, numerous nanomedicines are currently under clinical trials worldwide.

Curcumin (Cur) has been demonstrated to have wide pharmacological window including anti-oxidant and anti-inflammatory properties. However, phototoxicity under sunlight exposure and poor biological availability limits its applicability. We have synthesized biodegradable and non-toxic polymer-poly (lactic-co-glycolic) acid (PLGA) encapsulated formulation of curcumin (PLGA-Cur-NPs) of 150 nm size range. Photochemically free curcumin generates ROS, lipid peroxidation and induces significant UVA and UVB mediated impaired mitochondrial functions leading to apoptosis/necrosis and cell injury in two different origin cell lines viz., mouse fibroblasts-NIH-3T3 and human keratinocytes-HaCaT as compared to PLGA-Cur-NPs. Molecular docking studies suggested that intact curcumin from nanoparticles, bind with BAX in BIM SAHB site and attenuate it to undergo apoptosis while upregulating anti-apoptotic genes like BCL2. Real time studies and western blot analysis with specific phosphorylation inhibitor of ERK1 and AKT1/2/3 confirm the involvement of ERK/AKT signaling molecules to trigger the survival cascade in case of PLGA-Cur-NPs. Our finding demonstrates that low level sustained release of curcumin from PLGA-Cur-NPs could be a promising way to protect the adverse biological interactions of photo-degradation products of curcumin upon the exposure of UVA and UVB. Hence, the applicability of PLGA-Cur-NPs could be suggested as prolonged radical scavenging ingredient in curcumin containing products.

In the original version of this article, Vikas Srivastava’s last name was spelled incorrectly.

Co-delivery of anticancer drugs and nucleic acid can improve therapeutic potential by modulating apoptosis pathways for the treatment of cancer. We synthesized an amphiphilic carrier to encapsulate two drugs and one siRNA for co-delivering nanoparticles (NPs) to colon cancer cells. NPs carrying multiple drugs along with siRNA is challenging and thus, rare in literature. Therefore, anticancer efficacy and synergy between multiple drugs and siRNA are important to study. Specifically, in this study, NP containing doxorubicin (DOX), aspirin (Asp) and siRNA targeting BCL-2 were prepared and characterized. The NPs demonstrated enhanced anticancer activity against the colon cancer cell line (HCT-116) compared to other cancer cell lines. Multiple drugs (DOX and Asp) and BCL-2 siRNA loaded NPs synergistically induced apoptosis in HCT-116 cells as evident by an increase in G2/M phase cells and decrease in mitochondrial membrane potential (MMP). Chou-Talalay analysis revealed strong synergistic interaction in all doses of NPs. Therefore, multiple drugs and siRNA loaded NPs significantly inhibited HCT-116 cell growth and hence could be a potential candidate for the treatment of colon cancer.

Cosmeceutical-based industries are the fast-growing field, and nanotechnology played an important role in cosmeceutical growth. Nanotechnology-based cosmeceuticals have more advantages over traditional products. Nanotechnology offers different varieties of products with enhanced bioavailability of active component which increase visual look of cosmeceutical products for a longer period of time. Its application covers a wide range of cosmeceutical products ranging from photoaging, hyperpigmentation, wrinkles, hair, etc. However, augmented demands of nanotechnology in cosmetic industry have prominent apprehension regarding the plausible diffusion of nanoparticles in the dipper skin, thus possible side effects to the human skin. Herein, a brief overview of the various novel nanocarriers for cosmeceuticals like liposomes, nanoemulsions, dendrimers, solid lipid nanoparticles (SLNs), inorganic nanoparticles, nanocrystals, etc., nanoparticle-based cosmeceutical products existing in the marketplace, possible health hazards caused by nanoparticles on exposure of nano-based cosmetics, and the recent regulatory rules applied to avoid the nanotoxicity are described.

Sparfloxacin (SPFX) is a broad spectrum antibiotic which inhibits bacterial DNA gyrase enzyme activity. However, photodegradation in the presence of UVA limits its antibacterial activity and induces phototoxicity. Thus, to encounter this problem, we have developed poly d,l-lactic-co-glycolic acid (PLGA) loaded SPFX nanoparticles. Here, we have performed a comparative antibacterial activity of SPFX and its nanoparticles (NPs) through molecular docking and plate sensitivity assay. Under environmental UVA exposure, photoexcited SPFX significantly generates ROS, DNA damage and mitochondrial mediated cell death in comparison to PLGA-SPFX-NPs (nano SPFX) in human skin cell line (HaCaT). In presence of UVA, bulk SPFX induced cell cycle arrest with appearance of sub-G1 peak showing apoptosis while nano SPFX did not show any change. SPFX triggered apoptosis via alteration in membrane integrity of mitochondria and lysosome in comparison to PLGA-SPFX-NPs. Involvement of mitochondrial mediated cell death was confirmed by down-regulation of anti-apoptotic Bcl-2 and procaspase-3 and upregulation of pro-apoptotic Bax, cytochrome-c and caspase-3 proteins expression. Specific caspase inhibitor, Z-VAD-FMK showed involvement of caspase cascade pathway in apoptosis. Our finding suggests that controlled release of SPFX from PLGA-SPFX-NPs can reduce its side effects and enhance its antibacterial activity. Thus, nanotization of fluoroquinolones will be a significant step to reduce the problem of resistance and phototoxicity of this group.

Combination of chemopreventive and/or therapeutic agents is the imminent smart approach to cope up with cancer because it may act on multiple targets through different pathways. In the present study, we have synthesized multiple chemopreventive and/or therapeutic agents (Curcumin, Quercetin and Aspirin) loaded nanoparticles by simple cation-anion interaction among the amine groups of chitosan (CS) and phosphate groups of sodium hexametaphosphate (SHMP). These nanosized bioactive materials (CS-SHMP-CQA-NPs) were well characterized and found most effective in colon cancer cell line (HCT-116) compared to other cancer cell lines. Triplex chemopreventive and/or therapeutic agents-loaded NPs were synergistically inducing apoptosis in HCT-116 cells compared to two-chemopreventive agents-loaded NPs as evident by an increase in sub-G1 cells (percent), and chromatin condensation along with the decrease in mitochondrial membrane potential (MMP). Interestingly, Chou–Talalay analysis revealed that CS-SHMP-CQA-NPs showed strong synergistic effect in its all doses. Thus, our study demonstrates that nanoparticles based bioactive materials significantly inhibit the growth of HCT-116 cells and thus could be a promising approach for colon cancer chemoprevention., Graphical abstract Image 1, Highlights • Multiple antioxidants loaded nanoparticle base bioactive materials have been synthesized. • This nanoparticular bioactive materials (CS-SHMP-CQA-NPs) were well characterized and found most effective in colon cancer cell line (HCT-116) compared to other cancer cell lines. • Nanosized bioactivematerial inhibited HCT-116 cells synergistically, could be a promising approach for colon cancer chemotherapy.

Doxorubicin (DOX) is a well-known anticancer drug used for the treatment of a wide variety of cancers. However, undesired toxicity of DOX limits its uses. To address the issue of minimizing toxicity of DOX by making it targeted towards cancer cells, DOX was entrapped in self-assembled 6-O-(3-hexadecyloxy-2-hydroxypropyl)-hyaluronic acid (HDHA) nanoparticles. We hypothesized that by encapsulating the drug in biodegradable nanoparticles, its therapeutic efficacy would improve, if targeted against cancer cells. We synthesized cell receptor targeted, DOX loaded HDHA nanoparticles (NPs) and non-targeted DOX loaded O-hexadecylated dextran (HDD) nanoparticles (NPs) and characterized them for their entrapment efficiency, percent yield, drug load, surface morphology, particle size and in vitro drug release. The anticancer efficacy of DOX loaded HDHA-NPs was evaluated by measuring the changes in tumor volumes, tumor weights, and mean survival rate of Swiss albino mice grafted with Ehrlich's ascites carcinoma (EAC) cells. For this, the animals were given HDHA-DOX-NPs (1.5 mg/kg b.wt.) intravenously and a green tea polyphenol, Epigallocatechin-3-gallate (EGCG) (20 mg/kg b.wt.), orally through gavage. The targeted NP dose with EGCG significantly increased mean survival time of the animals and enhanced the therapeutic efficacy of the drug compared to the non-targeted NPs and free DOX. Further, we showed that these NPs (HDD and HDHA) were more active in the presence of EGCG than DOX alone in inducing apoptosis in EAC cells as evident by an increase in sub-G1 cells (percent), Annexin V positive cells and chromatin condensation along with the reduction in mitochondrial membrane potential (MMP). The study demonstrates that DOX loaded HDHA-NPs along with EGCG significantly inhibit the growth of EAC cells with ∼38-fold dose advantage compared to DOX alone and thus opens a new dimension in cancer chemotherapy.

Synthesis, structures, and catalysis studies of gold(I) complexes of N-heterocyclic carbenes namely, a di-O-functionalized [1-(2-hydroxy-cyclohexyl)-3-(acetophenone)imidazol-2-ylidene], a mono-O-functionalized [1-(2-hydroxy-cyclohexyl)-3-(benzyl)imidazol-2-ylidene] and a non-functionalized [1,3-di-i-propyl-benzimidazol-2-ylidene], are reported. Specifically, the gold complexes, [1-(2-hydroxy-cyclohexyl)-3-(acetophenone)imidazol-2-ylidene]AuCl (1c), [1-(2-hydroxy-cyclohexyl)-3-(benzyl)imidazol-2-ylidene]AuCl (2c), and [1,3-di-i-propyl-benzimidazol-2-ylidene]AuCl (3b), were prepared from the respective silver complexes 1b, 2b, and 3a by treatment with (SMe2)AuCl in good yields following the commonly used silver carbene transfer route. The silver complexes 1b, 2b, and 3a were synthesized from the respective imidazolium halide salts by the reactions with Ag2O. The N-heterocyclic carbene precursors, 1-(2-hydroxy-cyclohexyl)-3-(acetophenone)imidazolium chloride (1a) and 1-(2-hydroxy-cyclohexyl)-3-(benzyl)imidazolium chloride (2a), were synthesized by the direct reactions of cyclohexene oxide and imidazole with chloroacetophenone and benzyl chloride respectively. The gold (1c, 2c, and 3b) and the silver (3a) complexes along with a new O-functionalized imidazolium chloride salt (1a) have been structurally characterized by X-ray diffraction. The structural studies revealed that geometries around the metal centers were almost linear in these gold and silver complexes. The gold (1c, 2c, and 3b) complexes efficiently catalyze ring-opening polymerization (ROP) of l-lactide under solvent-free melt conditions producing polylactide polymer of moderate to low molecular weights with narrow molecular weight distributions., © Elsevier

Synthesis, structure, and catalysis studies of two Au- and Ag-based initiators, namely, [3-(N-tert-butylacetamido)-1-(2-hydroxycyclohexyl)imidazol-2-ylidene]AuCl (1c) and [3-(N-tert-butylacetamido)-1-(2-hydroxycyclohexyl)imidazol-2-ylidene]AgCl (1b), for the bulk ring-opening polymerization Of L-lactide are reported. Specifically, gold complex 1c was obtained from silver complex 1b by the transmetalation reaction with (SMe(2))AuCl. Silver complex 1b was synthesized by the treatment of 3-(N-tert-butylacetamido)-1-(2-hydroxycyclohexyl)imidazolium chloride (1a) with Ag(2)O, Compound la was synthesized directly from the reaction of N-tert-butyl-2-chloroacetamide, cyclohexene oxide, and imidazole. The molecular structures of 1a, 1b, and 1c have been determined by X-ray diffraction studies. The formation of neutral monomeric complexes with linear geometries at the metal centers was observed for both 1b and 1c. The An and Ag complexes 1c and 1b successfully catalyzed the bulk ring-opening polymerization of L-lactide at elevated temperatures under solvent-free melt conditions to produce moderate to low molecular weight polylactide polymers with narrow molecular weight distributions. ((c) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006).

Ru(II) complexes with chelating ligands, 4',5'-ethylenedithiotetrathiafulvenyl[4,5-f][1,10]phenanthroline (L1), 1,3-dithiole-2-thiono[4,5-f][1,10]phenanthroline (L2), and 1,3-dithiole-2-ono[4,5-f][1,10]phenanthroline (L3), have been prepared and their structural, electrochemical, and photophysical properties investigated. Density functional theory (DFT) calculations indicate that the highest occupied molecular orbital of [Ru(bpy)2(L1)](PF6)2 (1) is located on the tetrathiafulvalene (TTF) subunit and appears ~0.6 eV above the three Ru-centered d orbitals. In agreement with this finding, 1 exhibits three reversible oxidations: the two at lower potentials take place on the TTF subunit, and the one at higher potential is due to the Ru(3+)/Ru(2+) redox couple. Complexes [Ru(bpy)2(L2)](PF6)2 (2) and [Ru(bpy)2(L3)](PF6)2 (3) exhibit only the Ru(3+)/Ru(2+)-related oxidation. The optical absorption spectra of all complexes reveal a characteristic metal-to-ligand charge transfer (MLCT) band centered around 450 nm. In addition, in the spectrum of 1 the MLCT band is augmented by a low-energy tail that extends beyond 500 nm and is attributed to the intraligand charge transfer (ILCT) transition of L1, according to time-dependent DFT calculations. The substantial decrease in the luminescence quantum yield of 1 compared to those of 2 and 3 is attributed to the reductive quenching of the emissive state via electron transfer from the TTF subunit to the Ru(3+) center, thus allowing nonradiative relaxation to the ground state through the lower-lying ILCT state. In the presence of O2, complex 1 undergoes a photoinduced oxidative cleavage of the central C═C bond of the TTF fragment, resulting in complete transformation to 3. This photodegradation process was studied with (13)C NMR and optical absorption spectroscopy.

The last decade has witnessed many advances in the coordination chemistry of tetrathiafulvalene (TTF). Various ligands, in which a metal-binding functionality is attached to the TTF unit, have been synthesized and used for the preparation of metal complexes. This Perspective summarizes the main types of TTF-containing ligands and their metal complexes and outlines the potential for the use of these building blocks in the design and assembly of multifunctional molecular materials.

Tetrathiafulvalene (TTF) and 1,10-phenanthroline have been fused together via a simple and efficient synthetic procedure that provides a new bidentate ligand, 4',5'-ethylenedithiotetrathiafulvenyl[4,5-f][1,10]phenanthroline (EDT-TTF-phen, 1). Its ruthenium(II) complex exhibits a unique packing of TTF subunits in the solid state. In an acetonitrile solution, [Ru(bpy)(2)(1)](PF(6))(2) undergoes facile oxidative cleavage of the C=C double bond, which cannot be observed in the dark or under anaerobic conditions. This points to the photocatalytic role played by the ruthenium(II) chromophore in this conversion.

Two new trans- and cis-[(NHC)(2)PdX(2)] (X=Cl, Br) complexes of N/O-functionalized N-heterocyclic carbenes employed in a highly convenient amine-free Sonogashira cross-coupling reaction in air in a polar mixed aqueous medium are reported. Specifically, the trans-[{1-benzyl-3-(3,3-dimethyl-2-oxobutyl)imidazol-2-ylidene}(2)PdBr(2)] (3) and cis-[{1-benzyl-3-(N-tert-butylacetamido)imidazol-2-ylidene}(2)PdCl(2)] (4) complexes effectively catalyzed the Sonogashira cross-coupling reaction of aryl iodides with substituted acetylenes in air in a mixed solvent (DMF/H(2)O, 3:1 v/v) under amine-free conditions. Interestingly, these trans- and cis-[(NHC)(2)PdX(2)] (X=Cl, Br) complexes, with two N-heterocyclic carbene ligands, exhibited superior activity compared with the now popular PEPPSI (pyridine enhanced precatalyst preparation, stabilization and initiation)-themed analogues, trans-[(NHC)Pd(pyridine)X(2)] (X=Cl, Br), 3 a and 4 a, with one N-heterocyclic carbene ligand and a "throw away" pyridine ligand in a trans disposition to each other. The higher activities of 3 and 4 compared with PEPPSI analogues 3 a and 4 a are attributed to more-electron-rich metal centers, as revealed by DFT studies, in the former complexes and is in concurrence with a more electron-rich metal center being effective in facilitating the oxidative addition of aryl halide, often a rate-determining step in palladium-mediated cross-coupling reactions. Complexes 3 and 4 were prepared from the corresponding silver analogues by transmetalation with [(cod)PdCl(2)], whereas the corresponding PEPPSI analogues 3 a and 4 a were obtained directly from the imidazolium halide salts by reaction with PdCl(2) in pyridine in the presence of K(2)CO(3) as base.

Synthesis, structure, bonding, and photoluminescence studies of a pair of neutral dimeric silver and gold complexes of a N/O-functionalized N-heterocyclic carbene ligand exhibiting closed-shell d10...d10 argentophilic and aurophilic interactions, are reported. In particular, dimeric complexes of the type {[1-(benzyl)-3-(N-tert-butylacetamido)imidazol-2-ylidene]MCl}2 [M = Ag (2); Au (3)] displayed attractive metallophilic interaction in the form of a close ligand-unsupported metal...metal contact [3.1970(12) A in 2; 3.2042(2) A in 3] as observed from X-ray diffraction study and also was further verified by low temperature photoluminescence study at 77 K that showed the characteristic emission [527 nm for 2; 529 nm for 3] owing to the metal...metal interaction. The nature of the metallophilic interaction in these complexes was further probed using computational studies that estimated the metal...metal interaction energy to be 12.8 (2) and 8.6 kcal/mol (3). Notably, the argentophilic interaction was found to be stronger than the aurophilic interaction in this series of neutral dimeric complexes. The complexes 2 and 3 were synthesized sequentially, with the silver 2 complex prepared by the reaction of the 1-(benzyl)-3-(N-tert-butylacetamido)imidazolium chloride with Ag2O in 66% yield, while the gold 3 complex was obtained by the transmetallation reaction of the silver 2 complex with (SMe2)AuCl in 86% yield.

Several new air-stable, convenient to handle and easily synthesized Pd based PEPPSI ( Pyridine Enhanced Precatalyst Preparation, Stabilization and Initiation) type precatalysts supported over N/O-functionalized N-heterocyclic carbenes (NHC) namely, trans-[1-(benzyl)-3-( N-t-butylacetamido) imidazol-2-ylidene] Pd( pyridine) Cl-2 ( 2), trans-[1-(2-hydroxy-cyclohexyl)-3( benzyl) imidazol-2-ylidene] Pd( pyridine) Cl2 ( 3) and trans-[1-(o-methoxybenzyl)-3-(t-butyl)imidazol-2-ylidene] Pd( pyridine) Br-2 ( 4), have been designed. Specifically, the Pd-NHC complexes, 2, 3 and 4, were conveniently synthesized from their respective imidazolium halide salts by the reaction with PdCl2 in pyridine in presence of K2CO3 as a base. A new imidazolium chloride salt, 1-(benzyl)-3-( N-t-butylacetamido) imidazolium chloride ( 1) was synthesized by the alkylation reaction of benzyl imidazole with N-t-butyl-2-chloroacetamide. The molecular structures of the imidazolium chloride salt, 1, and the Pd-NHC complexes, 2, 3 and 4, have been determined by X-ray diffraction studies. The density functional theory studies of the 2, 3 and 4 complexes were carried out to in order to gain insight about their structure, bonding and the electronic properties. The nature of the NHC-metal bond in these complexes was examined using Charge Decomposition Analysis (CDA), which revealed that the N-heterocyclic carbene ligands are effective r-donors. In addition, the catalysis studies revealed that the Pd-NHC complexes, 2, 3 and 4, are effective catalysts for the Suzuki-Miyaura type C-C cross-coupling reactions.

Synthetic and structural studies of Pd(II) and Au(I) complexes of a new O-functionalized N-heterocyclic carbene ligand, namely, 1-(o-methoxybenzyl)-3-tert-butylimidazol-2-ylidene, are reported. Specifically, the N-heterocyclic carbene precursor 1-(o-methoxybenzyl)-3-tert-butylimidazolium bromide (1a) was synthesized by the reaction of 2-methoxybenzyl bromide and tert-butylimidazole in 44% yield. The Au(I) and Pd(II) complexes [1-(o-methoxybenzyl)-3-tert-butylimidazol-2-ylidene]AuCl (1c) and [1-(o-methoxybenzyl)-3-tert-butylimidazol-2-ylidene]2PdCl2 (1d) were prepared in 77% and 89% yields, respectively, by the commonly used silver carbene transfer route from the silver complex {[1-(o-methoxybenzyl)-3-tert-butylimidazol-2-ylidene]2Ag}+Br- (1b). The silver complex 1b was in turn synthesized from the reaction of 1a with Ag2O. The molecular structures of the complexes 1c and 1d have been determined by X-ray diffraction studies, which revealed that the gold complex 1c possessed a linear geometry while the pall...